Drug intelligence / Profile preview

clostridium butyricum + lactobacillus acidophilus + bifidobacterium infantis

Development stage: Unknown
Lead developer: Miyarisan Pharmaceutical
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Clostridium butyricum + lactobacillus acidophilus + bifidobacterium infantis is a triple-strain live biotherapeutic product primarily developed and marketed in China for the treatment of intestinal dysbiosis and associated gastrointestinal disorders. The combination consists of Clostridium butyricum, which produces butyric acid to nourish the intestinal epithelium and inhibit pathogens; Lactobacillus acidophilus, which produces lactic acid to maintain an acidic environment; and Bifidobacterium infantis, a key commensal organism that supports immune function and barrier integrity. Together, these strains work synergistically to restore the natural gut flora, alleviate symptoms of acute and chronic diarrhea, and treat constipation or abdominal distension caused by microbial imbalance.

Brand names: Baisangle贝飞达
Other names: Triple viable bacteria of Clostridium butyricum, Lactobacillus and Bifidobacterium酪酸梭菌三联活菌

Beyond the preview

Go deeper on clostridium butyricum + lactobacillus acidophilus + bifidobacterium infantis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clostridium butyricum + lactobacillus acidophilus + bifidobacterium infantis.

Explore the full profile